Immunotherapy strategies based on programmed cell death protein 1 (PD-1), PD-1 ligand (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4) immune checkpoint inhibitors (ICIs) have been widely investigated in the last decade, representing substantial progress in the treatment of advanced NSCLC with respect to the traditional platinum-based chemotherapy (CT) regimens [4,5]. Here, CTLA4 is linked to non-small cell lung carcinoma.